Unveiling CQA Insights for mRNA, LNPs, and Viral Vectors by SEC and MALS With Novel 1000 Å Ultrawide Pore Particle Columns

This webinar highlights the crucial need for quality and integrity analysis, where SEC combined with MALS plays a vital role.

Register Free: https://www.chromatographyonline.com/lcgc_w/cqa

Event Overview:

The recent pandemic has accelerated advancements in medicine, particularly with nucleic acid-based therapies such as mRNA, LNP delivery systems, and viral vectors. Ensuring the quality and integrity of these therapeutics is crucial, highlighting the importance of size exclusion chromatography (SEC) combined with MALS. This webinar will focus on using 1000 Å ultrawide pore columns with MALS to analyze long-chain nucleic acids, LNPs, and viral vector formulations, covering methods for mRNA integrity, LNP heterogeneity, and aggregate analysis.

Key Learning Objectives:

• Create high-resolution, robust, multi-attribute techniques for analyzing mRNA integrity and aggregates
• Establish method conditions for analyzing the heterogeneity of intact lipid nanoparticles (LNPs)
• Conduct aggregate analysis and identify degradation pathways with high-efficiency, low-absorption hardware using the new 1000 Å ultrawide pore columns

Who Should Attend:

• Academic researchers involved in biophysical studies
• Academic researchers involved in gene therapy studies
• Protein, lipid nanoparticle, and gene therapy: development scientists and lab managers
• Protein, lipid nanoparticle, and gene therapy: QC scientists and lab managers
• Lab managers, senior scientists
• Government researchers involved in gene therapy and lipid nanoparticle research

Speakers:

Adam Crowe, PhD
Senior manager, analytical development
Precision NanoSystems, part of Cytvia

Adam Crowe, PhD, received his doctorate in biochemistry from the University of British Columbia. After serving briefly as a postdoc, he joined Precision NanoSystems, a part of Cytiva. Dr Crowe manages a multidiscipline team that is tasked with developing novel analytical assays for lipid nanoparticles (LNP) and nanomaterials for drug delivery. Dr Crowe and his team have increasingly leveraged cutting-edge technologies, such as LC-MS approaches, to tackle the complexities of LNP characterization. Their latest studies were focused on the detail characterization of impurities found in ionizable liquids.

Lavelay Kizekai, BS
Principal Scientist
Waters Corporation

Lavelay Kizekai, BS, is a principal scientist at Waters Corporation. He joined Waters in 2009 and has since applied himself to developing new LC methods, leading column technology product development work, and establishing insight-based QC procedures for Waters products. His primary area of focus is biomolecule separations using size-exclusion chromatography (SEC). He was a core member of the team that recently brought to market a column suited to platform methods for monoclonal antibodies and antibody-drug conjugates. He is currently leveraging these SEC technologies and even newer breakthroughs for the characterization of gene-based therapeutics by multiangle light scattering SEC-MALS.

Mandana Fasth, MS
Global Principal Product and Marketing Manager
Waters Corporation

Mandana Fasth, MS, is the global principal product and marketing manager at Waters Corporation. She received her master’s degree in biochemistry from Uppsala University in Sweden. With more than 20 years of experience working with biologics workflows such as size-exclusion chromatography and column development projects, she is well versed in training and supporting scientists with method development for characterization and purification of biologics.

Register Free: https://www.chromatographyonline.com/lcgc_w/cqa